BC Innovations | Sep 12, 2019
Distillery Therapeutics

Peptide-macrocycle conjugates for breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Hydroquinone macrocycle-peptide conjugates targeting CD51/CD61 could treat breast cancer by trapping polyamines, which promote cell proliferation and differentiation. The conjugates consist of pillararenes attached to the peptide sequence arginine-glycine-aspartate...
BC Extra | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma  Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
BC Week In Review | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
BC Extra | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
BC Week In Review | Jul 28, 2017
Clinical News

Cancer Prevention starts Phase II of CPP-1x to prevent gastric cancer

Cancer Prevention Pharmaceuticals Inc. (Tucson, Ariz.) began a Phase II trial of CPP-1X to prevent gastric cancer in patients with precancerous gastric lesions. The double-blind, placebo-controlled trial will evaluate 500 mg daily oral CPP-1X for...
BC Week In Review | Jun 23, 2017
Clinical News

IDMC recommends continuation of Cancer Prevention's Phase III FAP trial

Cancer Prevention Pharmaceuticals Inc. (Tucson, Ariz.) said an IDMC recommended continuation of the Phase III CPP FAP-310 trial evaluating eflornithine/sulindac (DFMO/sulindac, CPP-1X/sulindac) to treat familial adenomatous polyposis (FAP). The product is a combination of eflornithine...
BC Week In Review | Oct 3, 2016
Clinical News

Eflornithine: Phase III started

Orbus began the open-label, international Phase III STELLAR trial to compare 28 g/m 2 oral eflornithine every 8 hours for the first 2 weeks of each 3-week cycle plus oral lomustine every 6 weeks vs....
BioCentury | Aug 15, 2016
Emerging Company Profile

Restraining translation

Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead...
BC Innovations | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Spermidine/spermine N1-acetyltransferase 1 (SAT1; SSAT); ornithine decarboxylase (ODC)

Infectious disease INDICATION: Chikungunya virus; viral infection Studies in mammalian cell culture, fruit flies and zebrafish suggest promoting SAT1 expression or inhibiting ODC could help treat Chikungunya, Sindbis and Zika viral infections. In a hamster...
BC Week In Review | Apr 11, 2016
Clinical News

Eflornithine/sulindac: Completed Phase III enrollment

Cancer Prevention completed enrollment of 166 FAP patients in a double-blind, placebo-controlled, international Phase III trial comparing 750 mg oral eflornithine once daily plus 150 mg oral sulindac once daily vs. each of its components...
Items per page:
1 - 10 of 31